Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond

W M Kooloos; J A M Wessels; S M van der Kooij; C F Allaart; T W J Huizinga; H-J Guchelaar

doi:10.1136/ard.2008.096891

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Letter

Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Kooloos WM, Wessels JAM, van der Kooij SM, et al

Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond

Annals of the Rheumatic Diseases 2009;68:1371.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password